Study of AK119 in Subjects With Advanced Solid Tumors

NCT ID: NCT05173792

Last Updated: 2024-04-25

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 16 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-12-22
• Study Completion Date: 2023-05-22

Brief Summary

This is Phase 1, Multicenter, Open-Label, Dose-Escalation and Dose-Exploration Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of AK119 (Anti-CD73) in Subjects with Advanced or Metastatic Solid Tumors.

Conditions

Solid Tumor

Study Design

• Allocation Method: NA
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

AK119

Subjects will receive escalating doses of AK119 every 2 or 3 weeks.

Group Type: EXPERIMENTAL

AK119

Intervention Type: DRUG

Subjects will receive AK119 intravenously.

Interventions

AK119

Subjects will receive AK119 intravenously.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Age ≥ 18 years.

2. Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to1.

3. Life expectancy ≥12 weeks;

4. Females of childbearing potential must be willing to use a highly effective method of birth control for the duration of the study, and within 120 days after the last dose of investigational product.

5. Non-sterile males must be willing to use a highly effective method of birth control for the duration of the study and within 120 days after the last dose of investigational product.

6. Subjects must have histologically or cytologically confirmed advanced or metastatic solid tumor that is refractory or relapsed to the current standard therapies, or for which no effective standard therapy is available, or whereby standard therapy has been refused.

7. Subjects must have evaluable lesions according to RECIST v1.1.

8. Adequate organ function.

Exclusion Criteria

1. Prior malignancy active within the previous 3 years except for the tumor for which a subject is enrolled in the study, and locally curable cancers that have been apparently cured.

2. Receipt of the following treatments or procedures:

1. Anticancer small-molecule targeted agent (e.g., tyrosine kinase inhibitor) within 2 weeks prior to the first dose of investigational product;

2. Anti-PD-1/PD-L1 mAb within 4 weeks prior to the first dose of investigational product;

3. Prior use of approved or investigational anti-CTLA-4 therapy, anti-CD73 therapy or adenosine 2A receptor inhibitors, or any other antibody or drug targeting T cell costimulation or immune checkpoint pathways such as ICOS, or agonists such as CD40, CD137, GITR, OX40 etc.;

4. Other anticancer mAb within 4 weeks or 5 half-lives (whichever is less) prior to the first dose of investigational product;

5. Other anticancer therapy (e.g., chemotherapy, radiotherapy, etc.) within 4 weeks prior to the first dose of investigational product;

6. Any major surgery within 4 weeks prior to the first dose of investigational product;

7. Any other non-approved investigational product or procedure within 4 weeks prior to the first dose of investigational product, or concurrent participation in another therapeutic clinical study;

8. Any topical therapy (e.g., TACE, HAIC, TARE) within 4 weeks prior to the first dose of investigational product;

3. Subjects with history of brain metastases that have been treated may participate provided they show evidence of stable supra-tentorial lesions at Screening;

4. Brain stem metastasis, meningeal metastasis, spinal cord metasasis or compression;

5. Uncontrolled massive ascites, pleural effusion or pericardial effusion, as determined by the Investigator;

6. Known history of human immunodeficiency virus (HIV) infection;

7. Known active hepatitis B or C infections (Active hepatitis B is defined as a known positive Hepatitis B surface antigen [HBsAg] result. Active hepatitis C is defined by a known positive Hepatitis C virus [HCV] antibody with detectable HCV ribonucleic acid [RNA] results);

8. Active autoimmune diseases or history of autoimmune diseases that may relapse;

9. History of interstitial lung disease, noninfectious pneumonitis except for those induced by radiation therapies;

10. Patients with clinically significant cardio-cerebrovascular or venous thromboembolic disease;

12. History of severe hypersensitivity reactions to other mAbs;

13. Prior organ transplantation;

14. Any condition that required systemic treatment with corticosteroids (> 10 mg daily prednisone or equivalent) or other immunosuppressive agents within 14 days prior to the first dose of investigational product;

15. Receipt of live attenuated vaccines within 4 weeks prior to the first dose of investigational product; Note: seasonal vaccine for influenza which is generally inactivated is allowed;

16. Any other conditions that, in the opinion of the Investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Akeso

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jihui Hao, PhD

Role: PRINCIPAL_INVESTIGATOR

Tianjin Medical University Cancer Insitute & Hospital

Tianshu Liu

Role: PRINCIPAL_INVESTIGATOR

Shanghai Zhongshan Hospital

Locations

Fudan University Zhongshan Hospital

Shanghai, , China

Tianjin Medical University Cancer Institute & Hospital

Tianjin, , China

Countries

China

Other Identifiers

AK119-103

Identifier Type: -

Identifier Source: org_study_id